Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

BACKGROUND: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order to explore a potential synergism tha...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Cruz-Merino, L., Gion, M., Cruz, J., Alonso-Romero, JL., Quiroga, V., Moreno, F., Andrés, R., Santisteban, M., Ramos, M., Holgado, E., Cortés, J., López-Miranda, E., Cortés, A., Henao, F., Palazón-Carrión, N., Rodriguez, L. M., Ceballos, I., Soto, A., Puertes, A., Casas, M., Benito, S., Chiesa, M., Bezares, S., Caballero, R., Jiménez-Cortegana, C., Sánchez-Margalet, V., Rojo, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719636/
https://www.ncbi.nlm.nih.gov/pubmed/36463104
http://dx.doi.org/10.1186/s12885-022-10363-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719636/
https://www.ncbi.nlm.nih.gov/pubmed/36463104
http://dx.doi.org/10.1186/s12885-022-10363-3

Ejemplares similares